



AF/1600
Response Under 37 CFR §1.116
Expedited Procedure
Examining Group 1615

CASE TN1A CIP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited in the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Burton Rodney
Type or print name

Signature

Feb. 26, 2003
Date

TECH CENTER
1600/2900
MAR 05 2003

RECEIVED

10/ Reg for
Recs

Bet
3-13-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1615

ULLAH ET AL.

Examiner: Susan T. Tran

APPLICATION NO: 09/848,448

FILED: MAY 3, 2001

FOR: HIGH DRUG LOAD ACID LABILE PHARMACEUTICAL
COMPOSITION

Box AF
Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT AFTER FINAL REJECTION

Sir:

This is in response to the Final Official Action mailed January 24, 2003.

REMARKS

Claims 1, 4 to 24 and 27 to 31 are present for purposes of prosecution.

Reconsideration of the rejection of this application is respectfully requested in view of the following remarks.

Applicants' invention as claimed is defined as a pharmaceutical composition (Claim 5) which is a spheronized beadlet (Claim 1) which contains from about 80 to about 100% by weight of an acid labile medicament which is 2',3'-dideoxyinosine, and which may also include a disintegrant and/or a binder. In Claim 5, the beadlet composition is defined as including a core and an enteric coating therefor.